SOURCE: LeukoDx

LeukoDx

March 24, 2015 09:00 ET

LeukoDx Inc. Chosen as a 2015 Red Herring Top 100 Europe Finalist

TOWSON, MD and JERUSALEM, ISRAEL--(Marketwired - Mar 24, 2015) - LeukoDx Inc., the creator of the Accellix automated flow cytometry platform, announced today that it has been selected as a Finalist for Red Herring's Top 100 Europe award, a prestigious list honoring the year's most promising private technology ventures from the European business region.

Red Herring's Top 100 Europe list has become a mark of distinction for identifying promising new companies and entrepreneurs. Red Herring's editors were among the first to recognize that companies such as Facebook, Twitter, Google, Yahoo, Skype, Salesforce.com, YouTube, and eBay would change the way we live and work.

Finalists for the 2015 edition of the Red Herring 100 Europe award are selected by the Red Herring editorial team from a pool of hundreds from across Europe. The nominees are evaluated on 20 main quantitative and qualitative criterions: they include disruptive impact, market footprint, proof of concept, financial performance, technology innovation, social value, quality of management, execution of strategy, and integration into their respective industries.

"For LeukoDx this is sign of recognition that our strategy is right and that the product we are developing can have a very significant impact in the world of healthcare" says LeukoDx President & CEO, Julien Meissonnier. "I look forward to going to Amsterdam to present LeukoDx, and to meet the other innovative companies."

The finalists are invited to present their winning strategies at the Red Herring award forum in Amsterdam, on April 13-15, 2015. The Top 100 winners will be announced at a special awards ceremony on April 15, 2015 at the event.

About LeukoDx Inc.

LeukoDx's mission is to deliver cost-effective, highly sensitive and actionable diagnostic information at the point of care via a novel automated IVD flow cytometry platform. Founded in 2009, LeukoDx's technology is based on technology initially developed for NASA at CalTech. To date, the Company has developed a compact reader for single use test-specific cartridges, and an application for the rapid identification of sepsis, a condition associated with high morbidity and mortality with no existing rapid diagnostic test.

Contact Information

  • Contact:
    Julien Meissonnier
    President and CEO
    Tel: +972-2-674-4422
    Email: Email Contact